Haleon (NYSE:HLN) Rating Lowered to “Hold” at Wall Street Zen

Haleon (NYSE:HLN) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research firms also recently weighed in on HLN. Zacks Research upgraded Haleon from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a report on Wednesday, September 9th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Friday, September 25th. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 16th. Finally, Royal Bank Of Canada restated a “sector perform” rating on shares of Haleon in a research report on Tuesday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Haleon Trading Down 0.1%

HLN opened at $8.79 on Friday. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. The firm has a market cap of $38.68 billion, a price-to-earnings ratio of 22.55, a PEG ratio of 1.99 and a beta of 0.14. Haleon has a 12 month low of $8.65 and a 12 month high of $11.28. The stock has a fifty day moving average price of $9.65 and a 200-day moving average price of $9.55.

Institutional Trading of Haleon

Hedge funds and other institutional investors have recently made changes to their positions in the company. Western Wealth Management LLC purchased a new position in Haleon during the 1st quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC increased its stake in Haleon by 402.0% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after purchasing an additional 2,404 shares during the period. Parkside Financial Bank & Trust lifted its position in shares of Haleon by 20.4% during the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock worth $58,000 after purchasing an additional 1,055 shares in the last quarter. Fiduciary Financial Group LLC acquired a new stake in shares of Haleon during the second quarter worth about $97,000. Finally, Gryphon Financial Partners LLC purchased a new position in shares of Haleon in the first quarter valued at approximately $101,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer healthcare company headquartered in Weybridge, England. The company develops, manufactures and markets over-the-counter medicines, oral healthcare products, nutritional supplements and other consumer health products sold through pharmacies, retailers and e-commerce channels.

Its portfolio includes well-known brands such as Sensodyne, Polident and parodontax in oral healthcare; Advil, Panadol, Voltaren and Theraflu in pain relief and respiratory care; and Centrum and Emergen-C in vitamins, minerals and supplements.